The U.S. Food and Drug Administration approved Parsippany-based Teva Pharmaceuticals’ new dosage for under-the-tongue drug Cassipa, which is used for maintenance and treatment of opioid addiction, federal regulators announced.
With the new actions by the FDA, Teva will increase Cassipa’s dosage strength of 16 milligrams, and 4 milligrams for each of its active ingredients buprenorphine and naloxone.
FDA Commissioner Dr. Scott Gottlieb said the use of treatments for opioid dependence is critical given the widespread prevalence of dependence on powerful, opioid-based painkillers.
Drugs like Cassipa will allow patients to be weaned off these painkillers, in conjunction with counseling and therapy, according to Gottlieb.
“Despite what some may think, individuals who successfully transition onto medication-assisted treatment are not swapping one addiction for another,” Gottlieb said. “Opioid replacement therapy can be an important part of effective treatment. Opioid use disorder should be viewed similarly to any other chronic condition that is treated with medication.”
Teva announced in July it was moving its U.S. headquarters from Pennsylvania to Parsippany after the New Jersey Economic Development Authority awarded it a 10-year, $40 million tax incentive.
The relocation is expected to add 843 jobs in the state and retain 232 employees.